A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Breast cancer patients are at a particularly high risk of cardiotoxicity from chemotherapy having a detrimental effect on quality-of-life parameters and increasing the risk of mortality. Prognostic biomarkers would allow the management of therapies to mitigate the risks of cardiotoxicity in vulnerable patients and a key potential candidate for such biomarkers are microRNAs (miRNA). miRNAs are post-transcriptional regulators of gene expression which can also be released into the circulatory system and have been associated with the progression of many chronic diseases including many types of cancer. In this review, the evidence for the potential application of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity (CIC) in breast cancer patientsis evaluated and a simple meta-analysis is performed to confirm the replication status of each reported miRNA. Further selection of miRNAs is performed by reviewing the reported associations of each miRNA with other cardiovascular conditions. Based on this research, the most representative panels targeting specific chemotherapy agents and treatment regimens are suggested, that contain several informative miRNAs, including both general markers of cardiac damage as well as those for the specific cancer treatments.

Related collections

Most cited references 151

Record: found
Abstract: found
Article: found

Is Open Access

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J L Page, Joanne E McKenzie, Patrick Bossuyt … (2024)

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.

0 comments Cited 13040 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation

Jacob O'Brien, Heyam Hayder, Yara Zayed … (2018)

MicroRNAs (miRNAs) are a class of non-coding RNAs that play important roles in regulating gene expression. The majority of miRNAs are transcribed from DNA sequences into primary miRNAs and processed into precursor miRNAs, and finally mature miRNAs. In most cases, miRNAs interact with the 3′ untranslated region (3′ UTR) of target mRNAs to induce mRNA degradation and translational repression. However, interaction of miRNAs with other regions, including the 5′ UTR, coding sequence, and gene promoters, have also been reported. Under certain conditions, miRNAs can also activate translation or regulate transcription. The interaction of miRNAs with their target genes is dynamic and dependent on many factors, such as subcellular location of miRNAs, the abundancy of miRNAs and target mRNAs, and the affinity of miRNA-mRNA interactions. miRNAs can be secreted into extracellular fluids and transported to target cells via vesicles, such as exosomes, or by binding to proteins, including Argonautes. Extracellular miRNAs function as chemical messengers to mediate cell-cell communication. In this review, we provide an update on canonical and non-canonical miRNA biogenesis pathways and various mechanisms underlying miRNA-mediated gene regulations. We also summarize the current knowledge of the dynamics of miRNA action and of the secretion, transfer, and uptake of extracellular miRNAs.

0 comments Cited 1335 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Power failure: why small sample size undermines the reliability of neuroscience.

Katherine S. Button, John Ioannidis, Claire Mokrysz … (2014)

A study with low statistical power has a reduced chance of detecting a true effect, but it is less well appreciated that low power also reduces the likelihood that a statistically significant result reflects a true effect. Here, we show that the average statistical power of studies in the neurosciences is very low. The consequences of this include overestimates of effect size and low reproducibility of results. There are also ethical dimensions to this problem, as unreliable research is inefficient and wasteful. Improving reproducibility in neuroscience is a key priority and requires attention to well-established but often ignored methodological principles.

0 comments Cited 1149 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Athos Antoniades: athos.antoniades@stremble.com

Journal

Journal ID (nlm-ta): Cardiooncology

Journal ID (iso-abbrev): Cardiooncology

Title: Cardio-oncology

Publisher: BioMed Central (London )

ISSN (Electronic): 2057-3804

Publication date (Electronic): 7 September 2022

Publication date PMC-release: 7 September 2022

Publication date Collection: 2022

Volume: 8

Electronic Location Identifier: 16

Affiliations

[1 ]Stremble Ventures Ltd, 59 Christaki Kranou, 4042 Limassol, Cyprus

[2 ]GRID grid.9594.1, ISNI 0000 0001 2108 7481, University of Ioannina, ; 45110 Ioannina, Greece

[3 ]GRID grid.489927.9, ISNI 0000000406443662, Bank of Cyprus Oncology Centre, ; 32 Acropolis Avenue, 2006 Strovolos, Nicosia, Cyprus

[4 ]GRID grid.4708.b, ISNI 0000 0004 1757 2822, European Institute of Oncology, , IRCCS and University of Milan, ; Milan, Italy

[5 ]GRID grid.411449.d, ISNI 0000 0004 0622 4662, National and Kapodistrian University of Athens, , Athens University Hospital Attikon, ; Athens, Greece

[6 ]GRID grid.9594.1, ISNI 0000 0001 2108 7481, 2nd Department of Cardiology, Faculty of Medicine, School of Health Sciences, , University of Ioannina, and University Hospital of Ioannina, ; Ioannina, Greece

[7 ]GRID grid.24381.3c, ISNI 0000 0000 9241 5705, Department of Oncology-Pathology, , Karolinska Institutet and University Hospital, ; Stockholm, Sweden

Article

Publisher ID: 142

DOI: 10.1186/s40959-022-00142-1

PMC ID: 9450324

PubMed ID: 36071532

SO-VID: 128ecdbb-7c7f-4d66-b9b5-b1df3f105c17

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 13 May 2022

Date accepted : 2 August 2022

Funding

Funded by: FundRef http://dx.doi.org/10.13039/100010661, Horizon 2020 Framework Programme;

Award ID: 945175

Custom metadata

Keywords: mirna,microrna,cardiotoxicity,breast cancer,chemotherapy,anthracycline

Data availability:

Keywords: mirna, microrna, cardiotoxicity, breast cancer, chemotherapy, anthracycline

A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

Read this article at

Abstract

Related collections

Karger: Oncology

Most cited references 151

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation

Power failure: why small sample size undermines the reliability of neuroscience.

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 243

Cited by 5

Most referenced authors 3,152